



CASE STUDY

Pancreatitis, complicated by a pancreatic pseudocyst associated with the use of valproic acid

Michiel L. Houben^a, Ingeborg Wilting^b, Hans Stroink^c,
Pieter J. van Dijken^{a,*}

^aDepartment of Paediatrics, St Elisabeth Hospital, P.O. Box 90151, 5000 LC Tilburg, The Netherlands

^bHospital pharmacy Midden-Brabant St Elisabeth Hospital and TweeSteden Hospital, Tilburg, The Netherlands

^cDepartment of Neurology, St Elisabeth Hospital and TweeSteden Hospital, Tilburg, The Netherlands

Received 22 September 2004; accepted 19 November 2004

KEYWORDS

Valproic acid;
Epilepsy;
Pancreatitis;
Pseudocyst;
Conservative
treatment

Summary A 12-year-old boy developed pancreatitis, complicated by a pancreatic pseudocyst, as an adverse reaction to valproic acid (VPA) treatment for epilepsy. Pancreatitis subsided within three weeks after discontinuation of VPA. The pancreatic pseudocyst was managed without surgery and resolved spontaneously in four weeks. Valproic acid was concluded to be the most probable cause, since no other explanation was found. According to the literature VPA is a rare but known cause of pancreatitis.

A computer-assisted literature search revealed seven previously reported cases of VPA-induced pancreatitis complicated by a pancreatic pseudocyst. Six of these patients were under 20 years of age. Four patients were treated conservatively; three needed cystostomy or external drainage. All patients recovered.

Patients using VPA, especially children, presenting with acute abdominal pain should be suspected of valproic acid-induced pancreatitis. If VPA induced pancreatitis is complicated by a pseudocyst, conservative treatment should be the first line of treatment.

© 2005 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Case

A 12-year-old boy presented at the pediatric ward of our hospital with intermittent upper abdominal pain that started two weeks before. The pain

attacks lasted for several minutes, and were less painful when the boy was lying still with his legs flexed. The attacks occurred 4-8 times a day. On examination the boy appeared moderately ill. His body weight was 45 kg and his temperature was 38 °C. He had no signs of jaundice nor did the skin reveal any haematomas. The bowel sounds were normal but there was some left upper abdominal tenderness. The liver and spleen were not enlarged, nor were any abnormal masses felt.

* Corresponding author. Tel.: +31 135392947; fax: +31 13 5359433.

E-mail address: p.dijken@elisabeth.nl (P.J. van Dijken).

The boy was known with cryptogenic localisation-related epilepsy with secondarily generalised seizures for which two years before valproic acid (VPA)-therapy was titrated up to 1500 mg a day (33 mg/kg). Since then the boy was free of seizures. VPA serum levels were compatible with a good compliance. The boy did not use any co-medication. There was no history of abdominal trauma.

Laboratory investigations showed a haemoglobin of 8.1 mmol/l (normal: 8.5-11.0 mmol/l), leukocytes $4.9 \times 10^9/l$ (normal: $3.5-11.0 \times 10^9/l$) and thrombocytes $161 \times 10^9/l$ (normal: $150-400 \times 10^9/l$). The ESR was 12 mm in the first hour. Serum amylase was 103 U/l (15-110 U/l). The serum lipase 278 U/l level was elevated (normal: 7-75 U/l). The urine amylase was 375 U/l (normal: <650 U/l). An abdominal ultrasound showed an enlarged pancreas with a homogeneous aspect. Based on clinical presentation, abdominal ultrasound and elevated serum lipase, the diagnosis pancreatitis was made. There were no other causes (infection, trauma, obstruction, hypercalcemia, elevated triglycerides nor medication (cotrimoxazol, metronidazol e.g.)) of pancreatitis found than the use of VPA. Furthermore the pancreatitis developed during VPA treatment. VPA is a known cause of pancreatitis.¹

In the absence of other obvious causes, VPA was considered the most probable explanation and was therefore discontinued.

Three weeks later and 14 days after the last dose of VPA, abdominal pain returned in increased intensity and frequency. The boy had become anorexic and had lost 3 kg body weight. Upon presentation he was nauseous, but did not vomit. His stools were normal. The serum amylase and lipase values had decreased (amylase 76 U/l, lipase 89 U/l). The urine amylase had decreased to 116 U/l. Ultrasound examination showed a left-sided upper abdominal cyst originating from the tail of the pancreas. Computed tomography confirmed the presence of a pancreatic pseudocyst with a diameter of 10 cm (Fig. 1). It was concluded that the pancreatitis had subsided, but the situation was now complicated by the development of a pseudocyst. For the pancreatic pseudocyst conservative treatment with analgesics and a low fat diet was instituted. The abdominal complaints gradually resolved and an ultrasound four weeks later showed complete resolution of the pancreatic pseudocyst. After discontinuation of VPA, the epilepsy was treated with subsequently levetiracetam, lamotrigine and clobazam without success. A rechallenge with VPA was considered. Because of the severity of a pancreatitis (20% leads to multi-organ failure and



Figure 1 Abdominal computed tomography showing a pancreatic pseudocyst (C) originating from the tail of the pancreas (P).

5-10% results in death) and the high risk of recurrence,¹⁻³ a rechallenge was not performed. Finally, after the introduction of topiramate, the boy only experienced auras, but no generalised seizures anymore.

Discussion

We describe the history of a 12-year-old boy in whom a pancreatitis, complicated by a pancreatic pseudocyst, developed after two years of monotherapy with VPA. Discontinuation of VPA led to a quick disappearance of complaints and normalisation of laboratory parameters. The boy did not use other medication, nor were any other causes of pancreatitis found. The prompt recovery, upon discontinuation of VPA, and the absence of other known causes of the pancreatitis led to the conclusion that VPA is the causal factor for the pancreatitis in our patient.

VPA is an agent used for the treatment of epilepsy, bipolar disorders and migraine. The drug is well tolerated by most people. Therapy may, however, be complicated by several adverse reactions. Common adverse reactions include weight gain, tremor, hair loss and thrombocytopeny. Rare but possibly very serious adverse reactions include hepatotoxicity, especially in very young retarded children, and pancreatitis, as observed in our patient.^{1,4,5}

The incidence of acute pancreatitis in childhood, in general, is estimated at 2.0-2.7 per 100,000 per year.² Pancreatitis complicated by pancreatic pseudocysts (a collection of amylase-rich, lipase-rich, and enterokinase-rich fluid) in childhood is

Table 1 Cases of valproic acid-related pancreatic pseudocyst.

Reference	Age (y)	Sex	Duration of VPA therapy (months)	VPA-dose (mg/kg/d)	VPA-titre (mg/l)	Intervention	Outcome
4	19	M	16	23	27-53	Cystogastrostomy	Recovered
17	7	F	7	50	87	Conservative ^a	Recovered
14	17	M	120	NA ^b	NA	Conservative	Recovered
16	4	M	1	NA	NA	External drainage	Recovered
15	12	M	39	27	NA	Cystoduodenostomy	Recovered
1	41	M	NA	5 g/d	NA	Conservative ^c	Recovered
8	9	F	>7	NA	73 ^d	Conservative ^a	Recovered
Our patient	12	M	24	33	132 ^d	Conservative	Recovered

^a laparotomy was performed on suspicion of acute appendicitis.

^b not available.

^c cholecystectomy for cholelithiasis and chronic cholecystitis.

^d 3 months before presentation.

reported predominantly after abdominal trauma. In general, a pseudocyst is a rare complication of pancreatitis.⁶⁻⁸ Drug-induced pancreatitis constitutes approximately 13% of all cases of acute pancreatitis in childhood. The development of pancreatitis has been related to more than 55 different drugs.⁹⁻¹² VPA definitely has been associated with pancreatitis, based upon a series of well documented cases.¹ VPA-induced pancreatitis occurs most frequently under the age of 20 and nearly half of the cases present within the first three months after initiation of treatment, though pancreatitis can also develop after years of treatment.¹ Since no dose nor serum level dependency has been demonstrated for VPA-induced pancreatitis, the reaction is probably idiosyncratic,^{1,13} but the exact mechanisms remains unclear. Pancreatitis is an acute inflammatory process of the pancreas, with autodigestion i.e. the pancreas is injured by its own digestive enzymes.¹ Serum lipase is considered to be more specific for pancreatitis than amylase and remains elevated for a longer period.³ Routine measurements of serum amylase and lipase during VPA use are not recommended.^{2,8} On clinical suspicion of pancreatitis determining serum lipase levels can be helpful.

An Embase and Medline literature search was performed using the MESH terms pancreatitis, pseudocyst or cyst and valproic acid. To our knowledge, the occurrence of a pancreatic pseudocyst as a complication of VPA-induced pancreatitis was first reported in 1984.⁵ Since then, six more cases have been described (Table 1).^{1,8,14-17} Seven of the eight patients (including our patient) were under the age of 20. Development of pancreatic pseudocyst, in the cases found in literature, occurred both early and late during treatment and were independent of VPA-dose

and titre. All patients recovered. Conservative treatment for the cyst was instituted in seven of eight cases; in one patient the pseudocyst was primarily treated surgically. In two patients an emergency laparotomy was performed on the suspicion of acute appendicitis, but a normal appendix was found.^{8,17} (Table 1: cases 2 and 7)

When VPA-induced acute pancreatitis is suspected, the drug should be discontinued immediately. Pancreatic pseudocysts are preferably treated conservatively, including adequate analgesia, intravenous fluids or nutrition and oral abstinence with nasogastric aspiration.⁸ Most pseudocysts regress during the first six weeks following diagnosis. Harm can be done by a more aggressive approach; drainage of the cyst can be complicated by infection and surgery can be complicated by intra abdominal leakage of pancreatic juice.^{6-8,18}

In conclusion, acute pancreatitis is a rare, severe adverse reaction to VPA-treatment. In the differential diagnosis of patients especially children, using VPA (regardless of the duration of VPA treatment) that present with abdominal pain, acute pancreatitis should be included in the differential diagnosis and VPA should be discontinued immediately. If VPA induced pancreatitis is complicated by a pseudocyst, conservative treatment should be the first line of treatment.

References

1. Asconape JJ, Penry JK, Dreifuss FE, Riela A, Mirza W. Valproate-associated pancreatitis. *Epilepsia* 1993;34(1): 177-83.
2. Pellock JM, Wilder BJ, Deaton R, Sommerville KW. Acute pancreatitis coincident with valproate use: a critical review. *Epilepsia* 2002;43(11):1421-4.

3. Grauso-Eby NL, Goldfarb O, Feldman-Winter LB, McAbee GN. Acute pancreatitis in children from Valproic acid: case series and review. *Pediatr Neurol* 2003;**28**(2):145-8.
4. Mallory A, Kern Jr F. Drug-induced pancreatitis: a critical review. *Gastroenterology* 1980;**78**(4):813-20.
5. Baskies AM. Case report: pancreatic pseudocyst associated with valproic acid therapy. *J Med Soc N J* 1984;**81**(5):399-400.
6. Firstenberg MS, Volsko TA, Sivit C, Stallion A, Dudgeon DL, Grisoni ER. Selective management of pediatric pancreatic injuries. *J Pediatr Surg* 1999;**34**(7):1142-7.
7. Kouchi K, Tanabe M, Yoshida H, et al. Nonoperative management of blunt pancreatic injury in childhood. *J Pediatr Surg* 1999;**34**(11):1736-9.
8. Queizan A, Hernandez F, Rivas S. Pancreatic pseudocyst caused by valproic acid: case report and review of the literature. *Eur J Pediatr Surg* 2003;**13**(1):60-2.
9. Wilmlink T, Frick TW. Drug-induced pancreatitis. *Drug Saf* 1996;**14**(6):406-23.
10. McArthur KE. Review article: drug-induced pancreatitis. *Aliment Pharmacol Ther* 1996;**10**(1):23-38.
11. Lankisch PG, Droge M, Gottesleben F. Drug induced acute pancreatitis: incidence and severity. *Gut* 1995;**37**(4):565-7.
12. Werth B, Kuhn M, Hartmann K, Reinhart WH. Drug-induced pancreatitis: experience of the Swiss Drug Adverse Effects Center (SANZ) 1981-1993. *Schweiz Med Wochenschr* 1995;**125**(15):731-4.
13. Gram L, Bentsen KD. Valproate: an updated review. *Acta Neurol Scand* 1985;**72**(2):129-39.
14. Braun E, Spannagel B, Bundschu HD. Unapparent course of pancreatitis with pseudocyst development and cholestatic jaundice in anticonvulsive therapy with valproate. *Klin Wochenschr* 1987;**65**(9):433-6.
15. Rose E, de Miscault G, Thome M, Boussard N. Acute pancreatitis caused by sodium valproate. Review of the literature apropos of a case in a child. *Pediatric* 1991;**46**(12):831-7.
16. Rosenberg HK, Ortega W. Hemorrhagic pancreatitis in a young child following valproic acid therapy. Clinical and ultrasonic assessment. *Clin Pediatr (Phila)* 1987;**26**(2):98-101.
17. Wyllie E, Wyllie R, Cruse RP, Erenberg G, Rothner AD. Pancreatitis associated with valproic acid therapy. *Am J Dis Child* 1984;**138**(10):912-4.
18. Karaguzel G, Senocak ME, Buyukpamukcu N, Hicsonmez A. Surgical management of the pancreatic pseudocyst in children: a long-term evaluation. *J Pediatr Surg* 1995;**30**(6):777-80.